ARTCLINE Raises €3.4M Seed for Allogeneic Immune Cell Therapies in Septic Shock

ARTCLINE Closes €3.4 Million Seed Round

ARTCLINE, a Rostock-based German biotech developing allogeneic immune cell therapies for critical care medicine, has raised €3.4 million in Seed funding. Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBG MV) participated in the round. The funding date is September 9, 2026.

What ARTCLINE Does

ARTCLINE develops allogeneic immune cell therapies for critical care medicine, with a focus on septic shock. Its flagship ARTICE therapy uses donor-derived immune cells in an extracorporeal procedure to support and stabilize key functions of a dysregulated immune system.

Donor cells are manufactured under GMP authorization, and the therapy incorporates CE-marked medical device components. The company was founded in 2007 as a spin-off from the University Medical Center Rostock.

Clinical Validation

ARTCLINE has completed the 142-patient ReActIF-ICE validation study. The company is preparing a commercial launch of ARTICE in early 2027.

The Round at a Glance

• Company: ARTCLINE
• Round type: Seed
• Funding amount: €3,400,000
• Currency: EUR
• Funding date: September 9, 2026
• Investor: Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBG MV)
• Domain: artcline.de

Why This Matters for the Market

Septic shock remains a critical care challenge with limited therapeutic options targeting the underlying immune dysregulation. ARTCLINE's approach — using donor-derived immune cells in an extracorporeal procedure — aims to support and stabilize immune system functions in these patients.

The completion of the 142-patient ReActIF-ICE validation study provides clinical evidence for the ARTICE therapy as the company moves toward commercialization. The planned commercial launch in early 2027 sets a near-term milestone for the program.

Manufacturing and Regulatory Position

ARTCLINE manufactures donor cells under GMP authorization, a requirement for cell therapy products intended for clinical use. The ARTICE therapy also uses CE-marked medical device components, reflecting the combination of biologic and device elements in its extracorporeal procedure.

Acquisition Angle

For acquirers in critical care, cell therapy, or medical devices, ARTCLINE represents a late-clinical-stage asset with a defined path to commercialization. The company's spin-off heritage from the University Medical Center Rostock and its completed validation study may make it attractive to strategic buyers seeking hospital-focused immune therapies.

The Seed round, backed by MBG MV, provides funding as ARTCLINE prepares for the commercial launch of ARTICE in early 2027. The involvement of a regional investment entity reflects local support for the Rostock-based biotech.

What to Watch

• Progress toward the commercial launch of ARTICE in early 2027
• Any additional regulatory milestones or manufacturing scale-up
• Further clinical or commercial partnerships

ARTCLINE's €3.4 million Seed round, announced September 9, 2026, supports its transition from clinical validation toward market entry in critical care medicine.